|MDACC Study No:||2012-1107(2010-0837LYMPHOMA) (clinicaltrials.gov NCT No: NCT01804686)|
|Title:||A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study|
|Principal Investigator:||Michael Wang|
|Study Description:||The goal of this clinical research study is to learn if PCI-32765 continues to |
be safe and effective when given long-term (beyond your previous PCI-32765
treatment) to treat lymphoma.
PCI-32765 is designed to block an enzyme that can cause cancer cells to grow.